Aura Biosciences (NASDAQ:AURA) Earns Buy Rating from HC Wainwright

Aura Biosciences (NASDAQ:AURA)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued on Thursday,Benzinga reports. They currently have a $22.00 target price on the stock. HC Wainwright’s target price indicates a potential upside of 132.31% from the company’s current price.

A number of other equities research analysts also recently issued reports on the stock. Evercore ISI upgraded shares of Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 16th. Cowen reissued a “buy” rating on shares of Aura Biosciences in a research note on Friday, October 18th. BTIG Research upped their target price on Aura Biosciences from $21.00 to $24.00 and gave the stock a “buy” rating in a research note on Friday, October 18th. Scotiabank lifted their price target on Aura Biosciences from $20.00 to $23.00 and gave the company a “sector outperform” rating in a research note on Friday, October 18th. Finally, JMP Securities lifted their price target on Aura Biosciences from $19.00 to $23.00 and gave the company a “market outperform” rating in a research note on Friday, September 13th. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $23.00.

Aura Biosciences Trading Down 5.0 %

Shares of AURA opened at $9.47 on Thursday. The stock has a market capitalization of $473.04 million, a PE ratio of -5.47 and a beta of 0.33. The firm’s 50 day moving average is $9.79 and its 200-day moving average is $8.51. Aura Biosciences has a 12 month low of $6.63 and a 12 month high of $12.38.

Aura Biosciences (NASDAQ:AURA) last released its earnings results on Tuesday, November 12th. The company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.02. Equities research analysts predict that Aura Biosciences will post -1.7 earnings per share for the current fiscal year.

Insider Activity

In other Aura Biosciences news, CTO Mark Plavsic sold 7,383 shares of the company’s stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $9.85, for a total value of $72,722.55. Following the completion of the transaction, the chief technology officer now owns 121,132 shares of the company’s stock, valued at $1,193,150.20. This represents a 5.74 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Julie B. Feder sold 25,131 shares of Aura Biosciences stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $12.03, for a total value of $302,325.93. Following the sale, the chief financial officer now directly owns 134,276 shares in the company, valued at $1,615,340.28. The trade was a 15.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 67,259 shares of company stock worth $780,699. Insiders own 5.40% of the company’s stock.

Institutional Investors Weigh In On Aura Biosciences

Institutional investors have recently added to or reduced their stakes in the business. American Century Companies Inc. acquired a new position in shares of Aura Biosciences during the second quarter worth $119,000. American International Group Inc. lifted its holdings in Aura Biosciences by 27.4% during the 1st quarter. American International Group Inc. now owns 17,579 shares of the company’s stock worth $138,000 after buying an additional 3,782 shares during the period. Virtu Financial LLC bought a new stake in shares of Aura Biosciences in the 1st quarter valued at about $144,000. SG Americas Securities LLC bought a new stake in shares of Aura Biosciences in the 3rd quarter valued at about $169,000. Finally, Barclays PLC increased its stake in shares of Aura Biosciences by 256.5% in the third quarter. Barclays PLC now owns 61,010 shares of the company’s stock valued at $544,000 after buying an additional 43,897 shares during the period. 96.75% of the stock is owned by institutional investors.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.